JUN 19, 2019 8:00 AM PDT

Exploring the genetic landscape of solid tumors using whole-genome copy number analysis

Speakers
  • Associate Professor, Pathology; Associate Director, Residency Program; Medical Director, Cytogenetics Laboratory AUMC.
    Biography
      Currently, Dr.Ravindra Kolhe is an Associate Professor in the Department of Pathology at the Augusta University in Augusta, Georgia, and divides his time between directing Molecular Pathology, Cytogenetics, Breast Pathology, teaching, and research. He is the CLIA laboratory director for the Georgia Esoteric & Molecular Labs and also serves as the Medical Director for the Cytogenetics Laboratory. As a Molecular and Genetic Pathologist, he is actively engaged in molecular and cytogenetic evaluation of patient samples as a part of the multi- disciplinary clinical team treating patients in a personalized and precision medicine model. As a Breast Pathologist, he provides expert opinions for the breast multidisciplinary tumor boards, consultation and second opinion to difficult breast cancer patients referred to Georgia Cancer Center. Dr. Kolhe is an physician-scientist with expertise in basic mechanisms of tumor immunology, including tolerogenic DCs, Tregs, and the indoleamine 2,3-dioxygenase pathway He has over 160 publications, including peer-reviewed articles, abstracts and invited reviews most in the realm of the molecular pathology of various malignancies.
    • Senior Research Scientist, Stanford University
      Biography
        Dr. Joanna Przybyl is a molecular and computational biologist whose research is focused on finding new diagnostic and prognostic markers in soft tissue sarcoma, and on identifying potential therapeutic targets in these tumors. She is a senior scientist in the laboratory of Dr. Matt van de Rijn in the Department of Pathology at Stanford University. In her research, Dr. Przybyl applies a variety of microarray and next generation sequencing techniques to study genomic, transcriptomic and epigenomic profiles of selected types of sarcomas.

      Abstract
      DATE:   June 19, 2019
      TIME:   8:00am PDT, 11:00am EDT
       
      Approximately 80% of all cancers are known to be affected by both somatic mutations and copy number changes. Furthermore, recent publications have shown that in certain types of cancers, copy number variations (CNVs) play a more important role than somatic mutations. It is therefore vital to map CNVs in solid tumor samples to fully profile tumors and identify new biomarkers.  This webinar will explore the importance of copy number analysis, specifically in the research of leiomyosarcoma (LMS) and melanoma, as well as highlight the use of Applied Biosystems™ OncoScan™ CNV assays for profiling copy number alterations across the genome.
       
      Leiomyosarcoma (LMS) is a malignant tumor showing smooth muscle differentiation. LMS tumors demonstrate substantial genomic instability that results in relatively high levels of DNA copy number changes. This portion of the webinar will show a workflow for the detection of CNVs in DNA extracted from FFPE samples, as well as demonstrate how copy number profiling may reveal intra- and inter-tumor heterogeneity in LMS and may allow for detection of tumor-matched CNVs in plasma specimens.
       
      For specific subsets of melanocytic proliferations, there exist conflicting and/or ambiguous features that preclude a definitive consensus diagnosis on histologic ground. The morphologic limitations in the diagnosis of these histologically borderline melanocytic tumors lead to both under and over diagnosis of melanoma. This portion of the webinar will discuss how whole genome studies have identified distinct oncogenic aberrations in melanoma and demonstrate the utility of whole-genome single nucleotide polymorphism microarrays (SNPM) in the evaluation of melanoma samples. 
       
      During the webinar, the speakers will:
      • Discuss the importance of copy number analysis in LMS and melanoma and its relevance for identifying biomarkers in cancers
      • Provide their own data on copy number changes found in LMS and melanoma and how these analyses have informed their work
      • Highlight the technologies they use to identify relevant and informative copy number changes in LMS and melanoma

       

       
      LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
       

      Show Resources
      You May Also Like
      SEP 10, 2020 9:00 AM PDT
      C.E. CREDITS
      SEP 10, 2020 9:00 AM PDT
      Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
      OCT 29, 2020 6:00 AM PDT
      C.E. CREDITS
      OCT 29, 2020 6:00 AM PDT
      Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
      NOV 16, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      NOV 10, 2020 7:00 AM PST
      C.E. CREDITS
      NOV 10, 2020 7:00 AM PST
      DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
      C.E. CREDITS
      This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
      Loading Comments...
      Show Resources
      Attendees
      • See more